About Gemelli Biotech
Gemelli Biotech is a Healthcare company based in Los Angeles (United States) founded in 2018 by Ali Rezaie, Kapil Gupta, Ruchi Mathur, Mark Pimentel, and Matt Mitcho. Diagnostics and therapeutics for the human microbiome are provided. Gemelli Biotech has raised $23.03 million across 3 funding rounds from investors including Cedars Sinai, Blue Ox Healthcare Partners and Carolina Angel Network. Its chief executive, as recorded, is Matt Mitcho. Gemelli Biotech offers products and services including Precision Diagnostics. Its focus areas include Life Sciences, Gastroenterology, In Vitro Diagnostic Tests and Bowel Disease. Its legal entity is GEMELLI BIOTECH CORP. Its competitors include Chosen Diagnostics and Venaxis; 1 of its 2 listed competitors has raised funding.
Company details
Gemelli Biotech was founded in 2018 in Los Angeles, United States, within the biotechnology sector. Diagnostics and therapeutics focused on the human microbiome are developed, often in partnership with Cedars-Sinai Medical Center. Key products include ibs-smart, a blood test for irritable bowel syndrome variants, and sclero-smart, which assesses anti-vinculin antibody levels in systemic sclerosis and scleroderma patients. Further products remain in the pipeline for upcoming releases.
- Headquarters Los Angeles, United States
- Founders Ali Rezaie, Kapil Gupta, Ruchi Mathur, Mark Pimentel, Matt Mitcho
- SectorsHealthcare
- Email••••••••
- Website gemellibiotech.com
- Social LinkedIn X Facebook Instagram
- Legal Name Gemelli Biotech Corp.
- Total Equity Funding$23.03M (USD)
in 3 rounds
- Latest Funding Round$21.18M (USD), Series A
Dec 2021
- InvestorsCedars Sinai
& 3 more
Products & Services of Gemelli Biotech
Gemelli Biotech offers a comprehensive portfolio of products and services, including Precision Diagnostics.
Non-invasive tools for detecting biomarkers in GI diseases like SIBO.
Funding Insights of Gemelli Biotech
Gemelli Biotech has successfully raised a total of $23.03M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $21.18 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.03M
- Total Rounds 3
- Last Round Series A — $21.18M
- First Round $1.85M
(Jun 2019)
- Investors Count 4
All 3 funding rounds of Gemelli Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $21.18M | Series A | – | Blue Ox Healthcare Partners | |
| Mar 2021 | $5.5M | Debt – Conventional | – | – | – |
| Jun 2019 | $1.85M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Gemelli Biotech
Gemelli Biotech has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cedars Sinai, Blue Ox Healthcare Partners and Carolina Angel Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Commercial-ready healthcare innovators are targeted for private equity investments. | 2009 | blueoxhcp.com | New York, United States | |
Early-stage investment opportunities are facilitated for UNC-affiliated startups. | carolinaangelnetwork.com | Chapel Hill, United States | ||
Early-stage tech companies in Asia and the US are funded. | cerracap.com | Costa Mesa, United States | ||
Chain of multispeciality hospital | 1902 | cedars-sinai.org | United States |
Investor details for Gemelli Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gemelli Biotech
18 people are tracked at Gemelli Biotech (15 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Ali Rezaie | Co-Founder & Scientific Advisor | Leadership |
Kapil Gupta | Co-Founder & Scientific Advisor | Leadership |
Ruchi Mathur | Co-Founder & Scientific Advisor | Leadership |
Mark Pimentel | Co-Founder & Scientific Advisor | Leadership |
Matt Mitcho | Co-Founder & CEO | Leadership |
Corey Fournet | Director Of Business Development | Leadership |
Fab Wilfong | VP, Market Access | Leadership |
Kevin Roupp | Director Of Business Development | Leadership |
Barbra Dillon | Director, Marketing Operations | Leadership |
Todd Krzyzaniak | VP of Finance & Analytics | Leadership |
Jim Dodson | Director, Customer Service | Leadership |
Amy Klein | Director Of Business Development | Leadership |
Tony Steffes, CPA MBA | Director Of Business Development | Leadership |
Kat Magness | Director Of Business Development | Leadership |
Tina Mirka | Director Of Business Development | Leadership |
Paige Lindsay Betts | Brand Manager | Team |
Dave Hayden | Senior Manager Customer Support | Team |
Luis Pimentel | Senior Strategy And Data Analytics Manager | Team |
Complete people profiles for Gemelli Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Gemelli Biotech
3 dated milestones of Gemelli Biotech across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Gemelli Biotech is founded.
- Funding First funding round of $1.9M.
- Funding Latest funding round, Series A, of $21.2M.
Competitors of Gemelli Biotech
Gemelli Biotech has 2 listed competitors in our database, 1 of them funded. They include Chosen Diagnostics and Venaxis.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| chosendiagnostics.com | 2011 | New Orleans, United States | Developing a novel MDx kit to diagnose a severe bowel disorder in premature infants | |||
| venaxis.com | 2012 | Castle Rock, United States | $1.95M | In vitro diagnostic tests for appendicitis are developed by Venaxis. |
Detailed competitors of Gemelli Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Gemelli Biotech
The website of Gemelli Biotech (gemellibiotech.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▼ 29.6% vs previous month
Top companies in Gastroenterology
3 companies that operate in the same segment as Gemelli Biotech (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gemelli Biotech
Complete news archive for Gemelli Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gemelli Biotech
Gemelli Biotech was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Gemelli Biotech is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Matt Mitcho is the CEO of Gemelli Biotech, as recorded in our data. They have also founded this company.
Gemelli Biotech is a funded company, having raised a total of $23.03M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.85M, raised on Jun 2019.
Gemelli Biotech was founded in 2018 in Los Angeles, United States, within the biotechnology sector. Diagnostics and therapeutics focused on the human microbiome are developed, often in partnership with Cedars-Sinai Medical Center. Key products include ibs-smart, a blood test for irritable bowel syndrome variants, and sclero-smart, which assesses anti-vinculin antibody levels in systemic sclerosis and scleroderma patients. Further products remain in the pipeline for upcoming releases.
Gemelli Biotech's top competitors include Chosen Diagnostics and Venaxis.
Gemelli Biotech offers Precision Diagnostics.
Gemelli Biotech has 4 investors. Key investors include Cedars Sinai, Blue Ox Healthcare Partners, Carolina Angel Network, and CerraCap Ventures.
Gemelli Biotech operates through Gemelli Biotech Corp..